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Abstract
Anti-PM/Scl antibodies represent a specific serological marker 
for a subset of patients with scleroderma (Scl) and polymyositis 
(PM), and especially w ith the PM/Scl overlap syndrome (PM/ 
Scl). Anti-PM /Scl reactivity is found in 24%  of PM/Scl patients 
and is found in 3 -1 0 %  of Scl and PM patients. The PM/Scl 
autoantigen complex comprises 1 1 -1 6  different polypeptides. 
Many of those proteins can serve as targets of the anti-PM/Scl 
B-cell response, but most frequently the PM /Scl-100 and PM/ 
Scl-75 polypeptides are targeted. In the present study we 
investigated the clinical relevance of a major alpha helical PM/ 
S c l-100 epitope (PM1-a) using a newly developed peptide- 
based immunoassay and compared the immunological 
properties of this peptide with native and recombinant PM/Scl 
antigens. In a technical comparison, we showed that an ELISA 
based on the PM 1-a peptide is more sensitive than common 
techniques to detect anti-PM/Scl antibodies such as 
immunoblot, indirect immunofluorescence on HEp-2 cells and 
ELISA with recombinant PM/Scl polypeptides. W e found no
statistical evidence of a positive association between anti-PM1- 
a  and other antibodies, w ith the exception of known PM/Scl 
components. In our cohort a negative correlation could be found 
with anti-Scl-70 (topoisomerase I), anti-Jo-1 (histidyl tRNA 
synthetase) and anti-centromere proteins. In a multicenter 
evaluation we demonstrated that the PM 1-a peptide represents 
a sensitive and reliable substrate for the detection of a subclass 
of anti-PM/Scl antibodies. In total, 22 /40  (55%) PM/Scl 
patients, 27 /205  (13.2%) Scl patients and 3 /40  (7.5%) PM 
patients, but only 5 /2 88  (1.7%) unrelated controls, tested 
positive for the anti-PM1-a peptide antibodies. These data 
indicate that anti-PM 1-a antibodies appear to be exclusively 
present in sera from PM/Scl patients, from Scl patients and, to 
a lesser extent, from PM patients. The anti-PM1-a ELISA thus 
offers a new serological marker to diagnose and discriminate 
different systemic autoimmune disorders.
Introduction
System ic autoimmune diseases such as scleroderm a (Scl), 
polymyositis (PM), rheumatoid arthritis, system ic lupus ery­
thematosus (SLE) and mixed connective tissue disease are 
characterized by the occurrence of c ircu lating antibodies to 
defined intracellular targets [1]. Some of these autoantibodies 
represent useful diagnostic markers for a variety of systemic 
autoimmune diseases [1,2].
Antibodies targeting the PM /Scl complex serve as a marker for 
the PM /Scl overlap syndrome, where they are found in 24%  of 
sera, but they are also seen in 8%  of PM patients and in 3%  of 
Scl patients [3-6]. The PM /Scl complex was identified as the 
human counterpart of the yeast exosome and consists of 11­
16 po lypeptides w ith m olecular masses ranging from 20 to 
110 kDa [7-11]. PM /Scl-100, the human equivalent of the 
yeast Rrp6p, has been cloned by two independent groups and 
its key function during the 5 .8  S rRNA end formation has been 
described [12-14].
DM =  dermatomyositis; ELISA =  enzyme-linked immunosorbent assay; HCV =  hepatitis C virus; IIF =  indirect immunofluorescence; PBS =  phosphate- 
buffered saline; PM =  polymyositis; PM1-a =  alpha helical PM/Scl-100 epitope; RU =  relative units; Scl =  scleroderma; SLE =  systemic lupus 
erythematosus. R704
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In previous studies, the human immune response targeting the 
PM /Scl complex has been reported to be predominantly 
directed against tw o polypeptides w ith  apparent molecular 
masses of 100  kDa and 7 5  kDa [15]. In the past it has been 
shown that nearly all PM /Scl-positive sera contain autoanti­
bodies to the 100 kDa protein and that only about 5 0 -6 0 %  
react w ith the 75 kDa protein [7 ,8,15-17]. A  more recent study 
has shown that the P M /S cl-75 protein contains a previously 
unidentified N-terminal region that is important for the anti­
genicity of the protein [18]. The reactivity of sera w ith this new 
isoform of PM /S cl-75c is sim ilar to the conventional PM /Scl- 
100 protein [18]. Several other com ponents of the human exo- 
some, including hRrp4p, hRrp40p, hRrp41, hRrp42p, 
hR rp46p and hCsl4p, are also recognized by anti-PM /Scl anti­
bodies, but to a lesser extent [10,19].
In several studies during the past decade, we and others have 
attem pted to identify the epitopes on PM /Scl-100 that are rec­
ognized by the cognate autoantibodies [12 ,20-23 ]. The prime 
reactivity of an ti-P M /S cl-100 sera was localized to a domain of 
the protein represented by amino acids 2 3 1 -2 4 5  using mem­
brane-bound peptide arrays [22,23]. The amino acids con trib ­
uting to the antibody binding were identified by mutational 
analysis [22,23]. Based on these observations and on second­
ary structure predictions, a local alpha-helical structure has 
been proposed for this major P M /S cl-100 epitope [22,23].
The aim of this study was to develop an ELISA w ith a 15-mer 
peptide com prising the P M /S cl-100 major epitope as a sub­
strate, and to evaluate its sensitivity and specific ity for the 
detection of anti-PM /Scl antibodies.
Materials and methods
Serum samples
In the present study three different serum panels were used to 
analyze the accuracy of the alpha helical P M /S cl-100 epitope 
(PM 1-a) peptide in the ELISA. For the technical comparative 
study, 33  sera w ith anti-PM /Scl reactivity were preselected by 
indirect im munofluorescence on HEp-2 cells and cryopre- 
served monkey liver sections (Euroimmun, Lübeck, Germany) 
and by immunoblot w ith total cell extracts (Panel I). Panel II 
consisted of sera from a previous study and included patients 
w ith PM /Scl, patients w ith PM, patients w ith Scl, patients w ith 
dermatomyositis (DM) patients w ith melanoma and normal 
donors [18]. For the m ulticenter evaluation, serum samples 
were collected from patients w ith PM /Scl overlap syndrome (n 
=  40), from patients w ith Scl (n =  50), from patients w ith PM 
(n =  40) and from patients w ith various contro l diseases 
including rheumatoid arthritis (n =  69), SLE (n =  114), undif­
ferentiated connective tissue disease (n =  10), mixed connec­
tive tissue disease (n =  6), Hashimoto thyroiditis (n =  11), 
Grave's disease (n =  12), other autoimmune disorders (n =  8), 
and hepatitis C  virus infection (HCV) (n =  48) (Panel III).
PM /Scl patients were diagnosed based on the official PM and 
Scl criteria and were only considered true overlap patients if 
they fulfilled both the criteria for PM and fo r Scl [24 ,25]. All 
other patients w ith autoimmune disorders were classified 
according to the official criteria for each disease as also 
applied in a recent investigation [26]. Sera were stored in a liq­
uots at -80°C  until use and were shipped on dry ice. Collection 
of patient samples was carried out according to local ethics 
com m ittee regulations.
Antigens for ELISA
The identified sequence LDVPPALADFIHQ Q R of the PM /Scl- 
100 (accession number JH0796) major B-cell epitope cover­
ing amino acids 2 3 1 -2 4 5  was used to synthesize the PM 1-a 
peptide w ith an additional cysteine residue at the C-term inus 
using Fmoc chemistry [22]. Crude peptide obtained from pep­
tide synthesis was purified by high-performance liquid chro­
matography. The quality and purity of the peptide was 
assessed by mass spectrom etry and analytical high-perform ­
ance liquid chromatography. The m olecular mass was found at 
1824 .1167  Da (average; m onoisotopic mass =  1822 .9274  
Da) and a purity of 100%  was determ ined. The isoelectric 
point of the peptide was 4.0. Recombinant P M /S cl-100 
(Diarect AG, Freiburg, Germany), was expressed in 
Escherichia co li and purified via a His-tag, and the quality was 
ensured by immunoblot and checkerboard analysis of positive 
and negative sera in the ELISA [27].
Indirect immunofluorescence
Indirect im munofluorescence (IIF) was carried out using Bio- 
Chip-m osaics w ith HEp-2 cells and primate liver as substrates 
(lot number 1 0 1 16D; Euroimmun GmbH). Antibody titers 
were determ ined using 10-fold serial dilutions in PBS and the 
assay was performed according the manufacturer's 
instructions.
Immunoblotting
Total cell extracts from HEp-2 cells that were separated by 
SDS-PAG E and transferred onto nitrocellulose were used as 
substrate for im m unoblotting (lot numbers 01011a -88  and 
01011a-89 ; Euroimmun Gm bH). The identity of the PM /Scl 
antigens was ensured using PM /Scl index sera, which were 
previously characterized by several methods. Sera were 
diluted and incubated according to the manufacturer's 
instruction.
ELISA
The P M 1-a peptide was absorbed onto 96-well polystyrene 
plates (maxisorb; Nunc, Rosilke, Denmark) by overnight incu­
bation at 4°C  in 0.1 M carbonate buffer (pH 9.5). Different 
coating concentrations and different blocking, washing and 
incubation conditions were com pared to optimize the assay 
conditions. Finally, the evaluation of antibody binding to the 
P M 1-a peptide was performed as follows. Serum samples 
diluted 1:100 in dilution buffer at a volume of 100 jj,l/well were
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F igure  1
Correlation diagrams of PM1-a, PM/Scl-75a, PM/Scl-75c and PM/Scl-1 00. A panel of sera tested previously for reactivity to recombinant polymy­
ositis/scleroderma (PM/Scl) components (PM/Scl-75a, PM/Scl-75c and PM/Scl-100) was assayed for anti-PM1-a peptide reactivity in an ELISA 
[18]. Correlation diagrams are shown comparing the peptide ELISA with the recombinant proteins (a )-(c ) for all sera (n =  81) and (b )-(f)  for only 
the sera of PM/Scl patients (n =  36).
incubated for 30 min. A fte r washing three tim es w ith washing 
buffer, anti-human IgG conjugate was added to the wells (100 
jul/well) and incubated fo r 30 min. Surplus conjugate was 
removed by three washing cycles. The substrate was finally 
added to each well (100 ul/well) and incubated for 15 min. 
A fte r s topping the color reaction w ith stop solution, the 
absorbance was measured at 450  nm. All steps were carried 
out at room temperature.
A  highly positive index patient serum that was available in 
larger quantities was used to generate a calibrator. The sam ­
ple was diluted 1:200 to yield an optical density of about 2.0 
in the ELISA. The optical density of each patient sample was 
divided by the optical density of the calibrator and the result 
was m ultiplied by 10. For the technical comparison, the cut-off 
value of the prototype kits was based on the mean ±  three 
standard deviations of 12 healthy blood donors. During the 
m ulticenter study the cut-off was validated and optim ized by 
receiver operating characteristic analysis (see later).
All ELISAs using recombinant proteins were performed as 
already described, using recombinant proteins expressed in E. 
co li and purified using either a His-tag or ion-exchange chro­
matography [17,18].
Addressable laser bead immunoassay
M icrospheres em bedded w ith laser reactive dyes (Luminex 
Corporation, Austin, TX, USA) that were coupled w ith autoan­
tigens were part of a commercial kit (QUANTA Plex 8 TM; 
INOVA D iagnostics Inc., San Diego, CA, USA). This profile 
test allows for the sem iquantitative detection of autoantibod­
ies to chromatin, Jo-1, Rib-P, RNP, Scl-70, Sm, SS-A (Ro) and 
SS-B  (La). The assay was performed according to the manu­
facturer's instructions. Briefly, each test serum was diluted to 
1 /1000  and 50 |ul was added to a well of a m icrotiter plate, 
mixed w ith the antigen-coated beads that were preserved in 
the well, and incubated for 30 min. Then 50 |ul phycoerythrin- 
conjugated goat anti-human IgG (Jackson ImmunoResearch 
Laboratories Inc., W es t Grove, PA, USA) was added to each 
well and incubated for an additional 30  min. The reactivity of 
the antigen-coated beads was determ ined on a Luminex 100™ 
dual laser flow  cytom eter (Luminex Corporation). The cut-off 
for a positive test result was based on the reactivity of contro l 
samples. The contro l samples were titrated to provide high, 
medium, low and negative values. Further information is avail­
able online h ttp ://w w w .inovadx.com /deta ilfiles/708910.pd f.
Statistical evaluation of the results
The results obtained from the comparative study were evalu­
ated using Analyse-it software (Version 1.62; Analyse-it S o ft­
ware, Ltd, Leeds, UK). Receiver operating characteristic 
curves, positive predictive values and negative predictive val-
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Table  1
R esults o f th e  techn ica l com parison  o f in d irec t im m uno fluo rescence  (IIF), im m u n o b lo t and ELISA fo r  th e  de tec tio n  o f anti 
po lym yo s itis /sc le ro d erm a  (an ti-P M /S c l) an tib od ie s
Sample number IIF Immunoblot ELISA
Titer Pattern PM/Scl-75 PM/Scl-100 Other PM/Scl-100 PM1-
1 1:10000 FG, N ++ +++ 15.3 17.7
2 1:1000 FG, N + + 2.9 7.6
3 1:3200 FG, N ++ ++ 14.4 29.2
1:320 AMA
4 1:320 FG, N - + 1.1 4.7
5 1:1000 FG, N + + 2.2 12.1
6 1:3200 FG, N - - 0.6 2.3
7 1:1000 FG, N ++ +++ 5.2 13.3
8 1:1000 FG, N + + 2.3 12.7
9 1:3200 FG, N + +++ P38 15.5 36.1
10 - - + 1.7 4.0
11 1:1000 FG, N - ++ 19.2 2.4
12 1:1000 FG, N ++ + 1.2 3.2
13 1:3200 FG, N +++ +++ Ku86, Jo-1 6.5 10.6
14 1:3200 FG, N - ++ 2.1 5.9
15 1:3200 FG, N ++ +++ 11.4 22.5
16 1:1000 FG, N - + 3.6 8.5
17 1:1000 FG, N + ++ 3.2 15.0
18 1:3200 FG, N ++ ++ 6.1 11.8
19 n.d. n.d. - ++ 7.1 19.4
20 1:320 N - + 2.1 5.6
21 n.d. n.d. + + + ++ 4.1 12.8
22 1:10000 FG - + P38 0.7 1.5
1:10000 SPA
23 1:1000 N n.d. n.d. 0.5 2.7
24 n.d. n.d. ++ +++ 18.2 34.7
25 1:10000 N n.d. n.d. P38 0.5 2.0
1:1000 Rib
26 1:1000 N n.d. n.d. 1.9 8.4
27 n.d. n.d. + ++ 5.9 19.4
R707
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Table  1 (C on tinued )
R esults o f th e  techn ica l com parison  o f in d irec t im m uno fluo rescence  (IIF), im m u n o b lo t and ELISA fo r  th e  de tec tio n  o f a n ti­
po lym yo s itis /sc le ro d erm a  (an ti-P M /S c l) an tib od ie s
28 n.d. n.d. ++ +++ 20.9 37.3
29 1:1000 Hom n.d. n.d. Ku86, Cen, M2 0.6 0.8
1:100 N*
30 1:1000 N - + 0.6 1.4
31 1:3200 Hom, N - - 0.5 2.9
32 1:3200 N - - 0.5 1.3
33 1:320 FG, N + ++ 7.2 25.7
Number positive/tested 26/29 17/29 27/29 26/33 32/33
-, negative; +, weak positive; ++, positive; +++, strong positive; n.d., not determined; FG, fine granular; Hom, homogenous; SPA, spindle 
apparatus; N, nucleoli; AMA, anti-mitochondrial antibodies; Cen, centromere; Rib, ribosomal. * Primate liver.
ues, as well as the test efficiency, were calculated. Further­
more, the correlation coeffic ients between the immunoassays 
based on the different antigens were calculated.
Results
Technical comparison of IIF, immunoblot and ELISA for 
the detection of anti-PM/Scl antibodies
To compare the different techniques, 33  anti-PM /Scl sera 
preselected on the basis of their IIF pattern and/or immunoblot 
result were tested in prototype ELISA kits based on the full- 
length recombinant P M /S cl-100 polypeptide expressed in E. 
co li and on the synthetic P M 1-a peptide. In total, 26 /33  
(78.8% ) were positive in the ELISA w ith the recombinant pro­
tein and 3 2 /3 3  (97.0% ) were positive in the ELISA w ith the 
synthetic peptide. Results are summarized in Table 1. Based 
on the high sensitivity of the peptide-based ELISA in this tech ­
nical comparison, we evaluated the clinical accuracy of the 
assay in an extended m ulticenter study using clinically defined 
sera from various centers.
Correlation of anti-PM1-a with anti-PM/Scl-75a, PM/Scl- 
75c and PM/Scl-100 reactivity in ELISA
A panel of sera (n =  81) tested previously for reactivity to 
recombinant PM /Scl proteins (Panel II) was assayed for anti- 
P M 1-a peptide reactivity in the ELISA. The results were com ­
pared w ith the known reactivity of these sera w ith the recom ­
binant proteins [18]. W hen all assays were adjusted to the 
same specific ity (91.1% ), the clinical sensitivity for the PM /Scl 
overlap syndrome was 36 .1%  for PM1-a, was 27 .8%  for PM / 
S c l-75c  and was 25 .0%  for PM /Scl-100.
There was a clear correlation between the peptide reactivity 
and the reactivity of the sera w ith the recombinant proteins. 
Not surprisingly, the strongest correlation was observed w ith 
the anti-P M /S cl-100 reactivity (Fig. 1). W hereas the majority of 
the sera showed comparable reactivity in all four assays, some 
individual samples showed a higher reactivity to the 
recombinant proteins than to the synthetic peptide, and vice
versa. Overall, only one sample (from a patient w ith DM) was 
found that tested positive fo r the recombinant proteins but 
negative for the synthetic peptide. However, 11 sera that 
tested positive in the peptide ELISA remained undetected 
using the recombinant proteins.
W hen analyzing only the PM /Scl patients from this panel (36 / 
81), the correlation between the reactivity of the peptide and 
the recombinant proteins was even higher (PM /Scl-100, R2 =
0.82). Very importantly, no sera were found positive for PM / 
S c l-75c and/or P M /S cl-100 but negative fo r the PM /Scl pep­
tide in the PM /Scl patient group. Two samples were PM /Scl- 
75c-positive (new isoform), PM 1-a-positive and P M /Scl-100- 
negative. One sample reacted w ith P M /S cl-100 and PM 1-a 
but not w ith the PM /S cl-75 proteins. O f the PM /Scl sera, 
27 .8%  (10 /36) was positive fo r the peptide but was negative 
for all recombinant polypeptides.
Correlation with other autoantibodies
A statistical evaluation was performed using a patient cohort 
of 70 clinically defined PM /Scl sera and PM sera to evaluate 
correlations between anti-PM 1-a peptide antibodies and other 
autoantibodies in ELISA assays using recombinant proteins. 
No significant correlation was found w ith Ro-52, Ro-60, La or 
Mi-2 antibodies (Table 2). A nti-P M 1-a antibodies and anti-Jo-
1 reactivity were negatively correlated. In addition, a reduced 
number of samples from 28 patients w ith clinically defined 
PM /Scl were also tested in an addressable laser bead immu­
noassay for autoantibodies to chromatin, Rib-P, RNP, Scl-70 
and Sm, SS-A (Ro) and SS -B  (La) (QUANTA Plex 8 TM; 
INOVA D iagnostics Inc.). A lthough antibodies to chromatin, 
Rib-P and RNP were detected in some patients, none of these 
antibodies appeared to be coincident w ith anti-PM 1-a reactiv­
ity (Table 2).
Multicenter evaluation of the PM1-a ELISA
Sera from 40 clinically defined but serologically unselected 
patients w ith PM /Scl overlap syndrome, as well as from 205
R708
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Table  2
C o rre la tion  o f a n ti-P M 1-a  and o th e r know n a u toa n tib o d ie s
Number positive/all sera (% 
positive)
Number positive/PM1-a-positives 
(% positive)
Number positive/PM1-a-negatives 
(% positive)
P
Scl-70 0/28 (0) 0/15 (0) 0/13 (0) *
Sm 0/28 (0) 0/15 (0) 0/13 (0) *
Rib-P 1/28 (3.6) 1/15 (6.7) 0/13 (0) *
RNP 4/28 (14.4) 1/15 (6.7) 3/13 (23.1) *
Chromatin 1/28 (3.6) 1/15 (6.7) 0/13 (0%) *
Ro-52 18/70 (25.7) 6/19 (31.6) 12/51 (23.5) 0.7056
Ro-60 6/70 (8.6) 2/19 (10.6) 4/51 (7.8) 0.9018
La 3/70 (4.3) 1/19 (5.3) 2/51 (3.9) 0.6766
Mi-2 10/70 (14.3) 3/19 (15.8) 7/51 (13.7) 0.8693
Jo-1 16/70 (22.9) 1/19 (5.2) 15/51 (29.4) 0.0688
* Not calculated due to the limited number of samples.
Scl patients, 40 PM patients and various other contro ls (Panel 
III), were analyzed in the PM /Scl peptide ELISA (see Table 3 ). 
The results from all patients were used to calculate a receiver 
operating characteristic curve, which showed a clear d iscrim ­
ination between PM /Scl patients and various contro ls (Fig. 2). 
A t a selected cut-off value of 1.5 RU, 22 /40  (55% ) PM /Scl 
patients tested positive fo r an ti-PM 1-a antibodies displaying a 
reactivity of up to 11.6 RU w ith a mean value of 3.1 ±  3.2 RU 
(Table 3). Patients from related disorders including Scl and 
PM showed a lower mean reactivity com pared w ith the overlap 
patients but a higher reactivity than more unrelated controls. In 
total, 2 7 /2 0 5  (13.2% ) scleroderm a patients (mean 0.7 ±  1.3 
RU) and 3 /4 0  (7.5% ) PM patients (mean 1.0 ±  1.1 RU) tested 
positive, while 3 /1 1 4  (2.6% ) patients w ith SLE and 2 /48  
(4.2% ) patients w ith HCV infection had anti-PM 1-a 
antibodies. None of the remaining contro ls showed reactivity 
to the P M 1-a peptide in the ELISA (Table 3 , Fig. 3).
In total, 6.6%  contro l sera tested positive for an ti-PM 1-a anti­
bodies. This resulted in a diagnostic sensitivity of 55%  and a 
specific ity of 93 .4%  of the peptide ELISA (positive predictive 
value =  38.6% , negative predictive value =  96.5% , test effi­
ciency =  90.7% ). W hen Scl patients and PM patients were 
excluded from the group of contro ls 5 /2 8 8  (1.7% ) patients 
were positive, resulting in a specific ity of 98 .2%  (positive pre­
dictive value =  81.5% , negative predictive value =  94.0% , test 
efficiency =  92.9% ). These data indicate that, w ithin the assay 
parameters used here, anti-PM 1-a antibodies appear to be 
mainly present in sera from PM /Scl patients, from Scl patients, 
and to a lesser extent, PM patients.
Discussion
The aim of this study was to compare the autoantigenicity of 
the P M 1-a peptide that we have described previously [22,23] 
w ith that of native and recombinant P M /S cl-75 and PM /Scl-
100 polypeptides. The results of the technical comparison 
showed that the P M 1-a peptide ELISA is more sensitive than 
the ELISA tests based on the recombinant proteins, and than 
immunoblot and IIF experiments. Also, our results suggest that 
increased titers of autoantibodies directed to P M 1-a m ight be 
more prevalent in patients w ith the PM /Scl overlap syndrome 
and related diseases than autoantibodies to the full-length pro­
teins, which up to now were considered the most frequently 
present.
In the past, the presence of these antibodies in serum was 
generally m onitored by IIF w ith HEp-2 cells, by imm unodiffu­
sion assays w ith calf thymus extract and/or by immunoblot 
using extractable nuclear antigens [4,5,15]. All these tech­
niques allow  the detection of a w ide variety of autoantibodies 
present in patient serum [2]. The detection of anti-PM /Scl anti­
bodies by immunoblotting, however, is difficult, because the 
reactivity of the antibodies w ith particularly P M /Scl-75 in cell 
extracts is notoriously weak in immunoblot, which may be due 
to the importance of conformational ep itopes [15]. This obser­
vation could be confirm ed in the technical comparison of IIF, 
immunoblot and ELISA in the present study. In recent years, 
ELISA using recombinant P M /S cl-100 has become a common 
method to detect anti-PM /Scl reactivity because it can easily 
be applied in an automated setting.
S ince anti-PM /S cl-75 reactivity was previously detected only 
in patient sera that also contained anti-P M /S cl-100 autoanti­
bodies [15], this protein is usually not included in such assays. 
A  recent investigation has shown that also the use of an 
incomplete recombinant PM /Scl-75 polypeptide may have led 
to an underestimation of the d iagnostic value of the PM /Scl-75 
antigen [18].
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F igure  2
Receiver operating characteristic analysis of the PM1-a ELISA. Results 
obtained from three centers and based on 567 patients including poly­
myositis/scleroderma (PM/Scl) patients (n =  40), Scl patients (n =
205) and PM patients (n =  40) as well as other controls were used to 
calculate a receiver operating characteristic analysis (a) for all control 
samples and (b) for unrelated controls (without Scl and PM). The curve 
shows a clear discrimination between PM/Scl patient samples and vari­
ous controls as emphasized by an area under the curve value of 0.901 
(all controls) and 0.958 (unrelated controls). The differentiation 
between PM/Scl patients and controls was significantly improved when 
Scl patients and PM patients were excluded from the control group (b). 
SE, standard error.
of PM patients. Interestingly, this peptide also contains a gen­
eralized T-cell epitope pattern (ALADFIHQQR; amino acids 
2 3 6 -2 4 5 ) as well as several major histocom patibility complex 
epitopes [28-30].
Synthetic peptides represent ideal antigenic targets for immu­
noassays because they can easily be produced in high quality 
and quantity. Furthermore, less lot-to-lot variation will be 
observed since the production is not dependent on the bio log­
ical variation of native sources of antigens. More and more syn­
thetic peptides are being used in immunological assay 
systems to de tect autoantibodies. Som e of them show  higher 
specific ities and sensitivities than the corresponding assay 
w ith recombinant protein or native protein as substrate [23].
The com bined use of different PM /Scl antigens, including the 
recombinant P M /S cl-100 and the recently identified isoform of 
PM /Scl-75, as well as the P M 1-a peptide, may represent the 
most sensitive and specific  method to detect antibodies to the 
human exosome. Advances in multi-analyte technologies such 
as line assays, multiplex systems and micro-arrays a llow  for the 
development of sophisticated profile assays containing m ulti­
ple different antigens. This may improve the diagnosis of a 
variety of disorders, especially of autoimmune diseases since 
for most of those disorders no highly sensitive marker is avail­
able. The diagnosis of PM /Scl, Scl and PM might be improved 
by providing an antigen array that includes different PM /Scl 
antigens in com bination w ith S cl-70  (topoisomerase I), Ku70/ 
86, centrom ere proteins, RNA polymerase, N 0R -90 , Jo-1, Mi-
2, PL-7, PL-12 and fibrillarin.
Taken together, the use of the P M /S cl-100 synthetic peptide 
in an ELISA remarkably improves the clinical identification of 
patients w ith the PM /Scl overlap syndrome. A lthough the prev­
alence of autoantibodies recognizing most other exosome 
subunits is relatively low [8,10,11], the co-occurrence of anti­
bodies targeting different exosome subunits in patient sera 
m ight be indicative of intermolecular epitope spreading and 
m ight be a marker for the overlap syndrome. The co-occur­
rence of an ti-P M /S cl-100 and anti-PM /Scl-75 seems to be 
particularly associated w ith the PM /Scl overlap syndrome
[18], but whether the use of even more com ponents of the 
human exosome will further increase the sensitivity of these 
assays remains to be investigated.
W e recently characterized the antibody response to a major 
PM /Scl epitope and found that 14 /14  (100% ) samples w ith 
PM /Scl antibodies dem onstrated reactivity to the major 
epitope in a membrane-based peptide array [22 ,23]. W e have 
characterized the major PM /S cl-100 B-cell epitope at the 
amino acid level and identified the key amino acids involved in 
antibody binding [22 ,23]. Using this peptide as an antigen, we 
developed a highly sensitive and specific  ELISA system that 
detects a subpopulation of anti-PM /Scl antibodies present in 
55%  of PM /Scl patients, in 13.2%  of S cl patients and in 7.5%
Apart from patients w ith PM /Scl overlap syndrome and 
patients w ith Scl or PM alone, tw o HCV-positive and three 
SLE patients displayed reactivity to the P M 1-a peptide in 
ELISA. HCV infection has been associated w ith a plethora of 
immune and autoimmune perturbations [31]. A lthough the 
cause and effect remain to be proved, there are reports of 
HCV infection preceding or coincident w ith polyarthritis, rheu­
matoid arthritis, SLE, and PM/DM. The role of anti-PM 1 -a  anti­
bodies in HCV patients and SLE patients remain a m atter fo r 
further investigation. In the present study we found antibodies
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Table  3
R esults o f ELISA using P M 1-a pep tide  w ith  p o lym yo s itis /sc le ro d e rm a  and va rious co n tro l sera
Number (%) of anti-PM1-a-positive sera Mean value/standard deviation Top value
Polymyositis/scleroderma (n =  40) 22 (55) 3.1/3.2 11.6
Rheumatic disease controls (n =  452) 33 (7.3) 0.6/0.9 7.7
Polymyositis (n =  40) 3 (7.5) 1.0/1.1 7.4
Scleroderma (n =  205) 27 (13.2) 0.9/1.2 7.5
Rheumatoid arthritis (n =  69) 0 (0) 0.3/0.2 1.1
Mixed connective tissue disease (n =  6) 0 (0) 0.4/0.1 0.6
Undifferentiated connective tissue disease (n =  10) 0 (0) 0.3/0.0 0.4
Systemic lupus erythematosus (n =  114) 3 (2.6) 0.5/0.7 7.7
Other rheumatic diseases (n =  8) 0 (0) 0.3/0.1 0.6
Hepatitis C virus (n =  48) 2 (4.2) 0.5/0.5 2.6
Organ specific disorders (n =  23) 0 (0) 0.4/0.2 0.8
Hashimoto thyroiditis (n =  11) 0 (0) 0.3/0.2 0.8
Grave's disease (n =  12) 0 (0) 0.4/0.2 0.8
Healthy individuals (n =  4) 0 (0) 0.6/0.2 0.7
F igure  3
Reactivity of polymyositis/scleroderma (PM/Scl) patients and controls in the PM1-a ELISA. Results obtained from three centers and based on 567 
patients including PM/Scl patients (n =  40), Scl patients (n =  205) and PM patients (n =  40) as well as other controls were used to calculate com­
parative descriptive analysis. The diagram shows a significantly increased reactivity of the PM/Scl sera compared with the control groups. Compara­
tive descriptives show vertical box-plots for each sample, side by side for comparison. The blue line series shows parametric statistics: diamond, 
mean and the requested confidence interval around the mean; notched line, requested parametric percentile range. The notched box and whiskers 
show non-parametric statistics: notched box, median, lower and upper quartiles, and confidence interval around the median; dotted line, connects 
the nearest observations within 1.5 interquartile ranges (IQR) of the lower and upper quartiles. + and Q  possible outliers -  observations more than
1.5 IQR (near outliers) and more than 3.0 IQR (far outliers) from the quartiles. Vertical lines, requested nonparametric percentile range. SLE, sys­
temic lupus erythematosus; HCV, hepatitis C virus; RA, rheumatoid arthritis.
to the P M 1-a peptide present in 13.2%  of unselected sc le ro­
derma patients. In only a few  of those patients was a history of 
myositis documented. It is possible that the myositis was mild 
in the majority of patients and was com pletely overlooked by 
the examining clinician or that the antibody precedes the asso­
ciated clinical features [32]. W e therefore conclude that the 
com plete autoantibody profile is important fo r a careful exami­
nation of patients w ith rheumatic diseases and to access all 
their clinical features.
Frank and colleagues analyzed sera from 216 patients w ith idi­
opathic inflammatory myopathies to assess putative associa­
tions between anti-SS-A /Ro-52 and other autoantibodies. 
These included sera containing antibodies that recognize Jo-
1, Mi-2, PM /Scl, signal recognition particle, as well as the
Ava ilab le  on line  http://arthritis-research.eom/content/7/3/R704
scleroderma-related antibodies anti-topoisomerase I (Scl-70) 
and anti-centromere. A high proportion of sera that contain 
anti-Jo-1 antibodies, anti-signal recognition particle or anti- 
PM/Scl antibodies were found to contain antibodies to the 
Ro52 protein [33]. The reported association between anti-Ro- 
52 and anti-PM/Scl antibodies is not found in our cohort. 
Although our correlation study is based on a limited number of 
samples, we found no correlation between anti-PM/Scl anti­
bodies and anti-Ro52. In contrast, Yamanishi and colleagues 
reported an association of PM/Scl syndrome with anti-Ku anti­
body and rimmed vacuole formation [34]. Similar to this obser­
vation, we found that two out of 29 (6.9%) anti-PM/Scl- 
positive samples also were positive for anti-Ku86 antibodies. 
In a previous study it became evident that the PM/Scl-100 
major epitope shares some sequence homology to an amino 
acid stretch (amino acids 58 -72 ) of the heterochromatin pro­
tein p25p, which is frequently the target of anti-chromo anti­
bodies from a subpopulation of patients also having anti­
centromere antibodies [22]. Although none of 14 PM1-a-pos- 
itive samples showed reactivity to the corresponding region of 
p25p, a more complex immunological relationship between 
the major PM/Scl-100 epitope and the corresponding p25p 
peptide cannot be excluded. More samples with anti-PM/Scl 
and anti-chromo antibodies have to be tested for cross-reac­
tivity. Further studies are required to analyze the association of 
anti-PM1-a antibodies with other known autoantibodies.
Today's sophisticated epitope mapping methods will probably 
lead to the identification of additional peptides, which can be 
used as specific targets in diagnostic and therapeutic 
approaches to patient management. This may lead to a new 
scientific research area with high impact for the development 
of diagnostic and therapeutic products -  to the area of pep­
tide engineering.
Conclusion
In the present study, we showed that the detection of anti-PM/ 
Scl antibodies using an ELISA system based on a major PM/ 
Scl-100 epitope is remarkably improved compared with con­
ventional detection methods. It could be shown that a subpop­
ulation of PM/Scl antibodies directed against the PM1-a 
peptide is present in 55% of PM/Scl patients, in 13.2% of Scl 
patients and in 7.5% of PM patients. In rare cases anti-PM1-a 
reactivity was also found in patients suffering from HCV, SLE 
or melanoma. Within our patient cohorts we found no statisti­
cal evidence of a positive association between anti-PM1-a 
and antibodies other than to PM/Scl components. Based on 
the results of the present study we conclude that anti-PM1-a 
antibodies are exclusively present in sera from patients suffer­
ing from Scl or PM and most frequently in patients with the 
PM/Scl overlap syndrome. We therefore conclude that the 
new anti-PM1-a ELISA test offers a new serological test that 
will improve the diagnosis of complex connective tissue 
disorders.
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